Posted by Michael Wonder on 17 Feb 2023
Iveric Bio announces FDA accepts new drug application and grants priority review for avacincaptad pegol for the treatment of geographic atrophy
16 February 2023 - PDUFA goal date is 19 August 2023.
IVERIC bio today announced that the US FDA has completed its filing review and accepted the company’s new drug application for avacincaptad pegol, a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to age-related macular degeneration.
